RBC Capital analyst Sean Dodge maintained a Buy rating on Tabula Rasa HealthCare (NASDAQ:TRHC) on Wednesday, setting a price target of $54, which is approximately 0.61% below the present share price of $54.33.
Dodge expects Tabula Rasa HealthCare to post earnings per share (EPS) of -$0.99 for the first quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Tabula Rasa HealthCare, with an average price target of $47.
The analysts price targets range from a high of $55 to a low of $40.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $70.51 million and a net profit of -$16.69 million. The company's market cap is $1.09 billion.
According to TipRanks.com, RBC Capital analyst Sean Dodge is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.4% and a 63.24% success rate.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.